Log in

Kalvista Pharmaceuticals News Headlines (NASDAQ:KALV)

$13.96
-0.19 (-1.34 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$13.84
Now: $13.96
$14.18
50-Day Range
$13.96
MA: $16.21
$18.56
52-Week Range
$9.86
Now: $13.96
$34.92
Volume43,330 shs
Average Volume78,624 shs
Market Capitalization$248.91 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24

Headlines

Kalvista Pharmaceuticals (NASDAQ KALV) News Headlines

Source:
DateHeadline
KalVista Pharmaceuticals to Present at SVB Leerink 9th Annual Global Healthcare ConferenceKalVista Pharmaceuticals to Present at SVB Leerink 9th Annual Global Healthcare Conference
finance.yahoo.com - February 19 at 9:24 AM
$9.98 Million in Sales Expected for Kalvista Pharmaceuticals Inc (NASDAQ:KALV) This Quarter$9.98 Million in Sales Expected for Kalvista Pharmaceuticals Inc (NASDAQ:KALV) This Quarter
www.americanbankingnews.com - February 16 at 3:40 AM
Zacks: Brokerages Expect Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Will Announce Earnings of -$0.56 Per ShareZacks: Brokerages Expect Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Will Announce Earnings of -$0.56 Per Share
www.americanbankingnews.com - February 14 at 2:47 PM
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Sees Significant Drop in Short InterestKalvista Pharmaceuticals Inc (NASDAQ:KALV) Sees Significant Drop in Short Interest
www.americanbankingnews.com - February 12 at 4:03 AM
KalVista Pharmaceuticals Provides Update on Diabetic Macular Edema ProgramsKalVista Pharmaceuticals Provides Update on Diabetic Macular Edema Programs
finance.yahoo.com - February 10 at 6:02 PM
Is KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Overpaid Relative To Its Peers?Is KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Overpaid Relative To Its Peers?
finance.yahoo.com - February 5 at 9:28 AM
The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDxThe Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx
finance.yahoo.com - February 4 at 8:41 AM
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Given Consensus Rating of "Buy" by BrokeragesKalvista Pharmaceuticals Inc (NASDAQ:KALV) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 3 at 2:30 AM
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Sees Significant Growth in Short InterestKalvista Pharmaceuticals Inc (NASDAQ:KALV) Sees Significant Growth in Short Interest
www.americanbankingnews.com - January 29 at 10:26 PM
BioLineRx Concludes Recruitment in Pancreatic Cancer StudyBioLineRx Concludes Recruitment in Pancreatic Cancer Study
finance.yahoo.com - January 23 at 12:48 PM
KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema FranchiseKalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise
finance.yahoo.com - January 13 at 5:06 PM
Introducing KalVista Pharmaceuticals (NASDAQ:KALV), The Stock That Zoomed 123% In The Last Three YearsIntroducing KalVista Pharmaceuticals (NASDAQ:KALV), The Stock That Zoomed 123% In The Last Three Years
finance.yahoo.com - January 6 at 4:56 PM
Will KalVista Continue to Surge Higher?Will KalVista Continue to Surge Higher?
finance.yahoo.com - January 2 at 3:50 PM
Here is What Hedge Funds Think About KalVista Pharmaceuticals, Inc. (KALV)Here is What Hedge Funds Think About KalVista Pharmaceuticals, Inc. (KALV)
finance.yahoo.com - December 12 at 10:48 PM
BRIEF-Kalvista Pharmaceuticals Reports Phase 2 Clinical Trial Results In Patients With Diabetic Macular EdemaBRIEF-Kalvista Pharmaceuticals Reports Phase 2 Clinical Trial Results In Patients With Diabetic Macular Edema
www.msn.com - December 9 at 10:26 PM
KalVistas KVD001 flunks mid-stage DME study; shares down 20% premarketKalVista's KVD001 flunks mid-stage DME study; shares down 20% premarket
seekingalpha.com - December 9 at 12:25 PM
KalVista Shares Sink On Failed Mid-Stage Study Of Diabetic Macular Edema DrugKalVista Shares Sink On Failed Mid-Stage Study Of Diabetic Macular Edema Drug
www.benzinga.com - December 9 at 9:52 AM
KalVista Pharmaceuticals, Inc. (KALV) Shares March Higher, Can It Continue?KalVista Pharmaceuticals, Inc. (KALV) Shares March Higher, Can It Continue?
finance.yahoo.com - December 6 at 9:49 AM
Should You Be Concerned About KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) Historical Volatility?Should You Be Concerned About KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) Historical Volatility?
finance.yahoo.com - December 5 at 12:43 PM
KalVista Pharmaceuticals Provides Business UpdateKalVista Pharmaceuticals Provides Business Update
finance.yahoo.com - November 13 at 8:59 AM
Is KalVista Pharmaceuticals, Inc. (KALV) A Good Stock To Buy?Is KalVista Pharmaceuticals, Inc. (KALV) A Good Stock To Buy?
finance.yahoo.com - November 6 at 6:43 PM
KalVista Sees Hammer Chart Pattern: Time to Buy?KalVista Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - October 21 at 7:37 AM
Have Insiders Been Buying KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares?Have Insiders Been Buying KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares?
finance.yahoo.com - October 16 at 9:12 AM
KalVista Group Sees Hammer Chart Pattern: Time to Buy?KalVista Group Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - October 1 at 4:24 PM
KalVista Pharmaceuticals Enters Oversold TerritoryKalVista Pharmaceuticals Enters Oversold Territory
finance.yahoo.com - September 23 at 4:22 PM
KalVista: An Early Stage Company Doing Things The Right WayKalVista: An Early Stage Company Doing Things The Right Way
seekingalpha.com - September 12 at 10:41 AM
KalVista Pharmaceuticals: Our VerdictKalVista Pharmaceuticals: Our Verdict
seekingalpha.com - September 4 at 5:52 AM
RBC sees 36% upside in Gilead in premarket analyst actionRBC sees 36% upside in Gilead in premarket analyst action
seekingalpha.com - July 29 at 9:38 AM
Monday 7/22 Insider Buying Report: KALV, DXCMonday 7/22 Insider Buying Report: KALV, DXC
www.nasdaq.com - July 22 at 4:26 PM
Moving Average Crossover Alert: KalVista PharmaceuticalsMoving Average Crossover Alert: KalVista Pharmaceuticals
finance.yahoo.com - July 17 at 10:56 AM
What Type Of Shareholder Owns KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV)?What Type Of Shareholder Owns KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV)?
finance.yahoo.com - July 10 at 4:41 PM
KalVista Pharmaceuticals Announces Changes to Board of DirectorsKalVista Pharmaceuticals Announces Changes to Board of Directors
finance.yahoo.com - July 1 at 10:25 AM
 KalVista Pharmaceuticals Announces Changes to Board of Directors KalVista Pharmaceuticals Announces Changes to Board of Directors
finance.yahoo.com - July 1 at 10:25 AM
Hedge Funds Have Never Been This Bullish On KalVista Pharmaceuticals, Inc. (KALV)Hedge Funds Have Never Been This Bullish On KalVista Pharmaceuticals, Inc. (KALV)
finance.yahoo.com - June 27 at 4:32 PM
KalVista Pharmaceuticals Presents KVD900 Data at European Academy of Allergy and Clinical ImmunologyKalVista Pharmaceuticals Presents KVD900 Data at European Academy of Allergy and Clinical Immunology
finance.yahoo.com - June 4 at 11:31 AM
KalVista Pharmaceuticals to Present at Jefferies Healthcare ConferenceKalVista Pharmaceuticals to Present at Jefferies Healthcare Conference
finance.yahoo.com - May 30 at 11:08 AM
KalVista Pharmaceuticals Presents KVD900 Data at C1-Inhibitor Deficiency and Angioedema WorkshopKalVista Pharmaceuticals Presents KVD900 Data at C1-Inhibitor Deficiency and Angioedema Workshop
finance.yahoo.com - May 28 at 11:12 AM
KalVista Pharmaceuticals to Present Data at Upcoming Scientific ConferencesKalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences
finance.yahoo.com - May 20 at 10:36 AM
KalVista Pharmaceuticals (KALV) Upgraded to Strong Buy: Heres WhyKalVista Pharmaceuticals (KALV) Upgraded to Strong Buy: Here's Why
www.nasdaq.com - May 17 at 11:06 AM
Rigel Initiates Enrollment in Pivotal Blood Disorder StudyRigel Initiates Enrollment in Pivotal Blood Disorder Study
finance.yahoo.com - May 17 at 11:06 AM
KalVista Pharmaceuticals (KALV) Upgraded to Strong Buy: Here's WhyKalVista Pharmaceuticals (KALV) Upgraded to Strong Buy: Here's Why
finance.yahoo.com - May 16 at 4:23 PM
BioCryst Pharmaceuticals: BCX7353 Phase 3 Results To Make Or Break This StoryBioCryst Pharmaceuticals: BCX7353 Phase 3 Results To Make Or Break This Story
seekingalpha.com - May 15 at 4:26 PM
Small Drug Stocks Outlook: Near-Term Prospects EncouragingSmall Drug Stocks Outlook: Near-Term Prospects Encouraging
finance.yahoo.com - May 6 at 10:32 AM
KalVista Pharmaceuticals Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019KalVista Pharmaceuticals Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019
finance.yahoo.com - April 30 at 11:03 AM
KalVista Pharmaceuticals to Present at Needham Healthcare ConferenceKalVista Pharmaceuticals to Present at Needham Healthcare Conference
finance.yahoo.com - April 3 at 11:18 AM
KalVista Pharmaceuticals Announces the Promotion of Benjamin L. Palleiko to Include Chief Business OfficerKalVista Pharmaceuticals Announces the Promotion of Benjamin L. Palleiko to Include Chief Business Officer
finance.yahoo.com - March 27 at 12:31 PM
What Makes KalVista Pharmaceuticals (KALV) a Strong Momentum Stock: Buy Now?What Makes KalVista Pharmaceuticals (KALV) a Strong Momentum Stock: Buy Now?
finance.yahoo.com - March 25 at 11:46 AM
Needham sees 24% upside for KalVista in permarket analyst actionNeedham sees 24% upside for KalVista in permarket analyst action
seekingalpha.com - March 20 at 4:16 PM
KalVista Pharmaceuticals Inc.KalVista Pharmaceuticals Inc.
www.barrons.com - March 15 at 11:55 AM
Is KalVista Pharmaceuticals’s (NASDAQ:KALV) 147% Share Price Increase Well Justified?Is KalVista Pharmaceuticals’s (NASDAQ:KALV) 147% Share Price Increase Well Justified?
finance.yahoo.com - March 14 at 4:24 PM
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: What is a Buy-Side Analyst?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel